Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Liver Diseases Therapeutics Market CAGR Outlook And Future Development
The liver diseases therapeutics market size has experienced robust expansion over recent years. Projections indicate it will increase from $15.18 billion in 2025 to $16.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. Historically, this expansion is linked to a significant occurrence of viral hepatitis infections, a rise in alcohol-related liver disease incidents, an initial dependence on antiviral and supportive treatments, restricted therapeutic choices for long-term liver ailments, and the expansion of hospital-provided liver care services.
The liver diseases therapeutics market is projected to experience substantial expansion in the coming years. This market is forecast to reach $24.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. This anticipated growth during the forecast period is driven by several factors, including the escalating prevalence of metabolic liver diseases, greater uptake of immunosuppressive and targeted therapies, the expansion of treatment pipelines for liver cancer, increasing recognition of the advantages of early intervention, and elevated healthcare expenditure on chronic liver diseases. Key trends anticipated during this period encompass a surge in demand for antiviral therapies for hepatitis treatment, an intensified focus on managing nafld and nash, the broader integration of immunotherapy in liver cancer treatment, the development of more combination drug therapies, and a heightened emphasis on strategies for long-term disease management.
Get A Free Sample Report With In-Depth Market Insights:
Liver Diseases Therapeutics Market Development Factors: What’s Supporting Demand?
The anticipated expansion of the liver disease therapeutics market is linked to the growing occurrence of liver ailments. Liver disease encompasses various conditions impacting the liver, and liver disease therapeutics are instrumental in managing these conditions through diverse treatment approaches. A notable example from December 2024, as reported by the Office for Health Improvement and Disparities, a UK-based government department, indicated that premature deaths due to alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984, an increase from 5,776 in 2022. Consequently, the escalating incidence of liver diseases is a primary driver for the expansion of the liver disease therapeutics market.
Liver Diseases Therapeutics Market Segmentation And Category Overview
The liver diseases therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers
Subsegments:
1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver
3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Liver Diseases Therapeutics Market Transformation Trends: What Innovations Are Driving Change?
Major companies in the liver disease therapeutics market are increasingly concentrating on innovative technologies, such as artificial intelligence, to assist clinicians in the early identification of liver fibrosis among patients as their disease progresses. Artificial intelligence in liver disease therapeutics involves the application of advanced computational algorithms and machine learning techniques to analyze medical data, thereby aiding in early detection, diagnosis, and the development of personalized treatment strategies for liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, launched hepatoSIGHT. This innovative AI-powered tool is designed to predict liver fibrosis in patients with chronic liver disease, serving as a case-finding and cohort mapping system to identify individuals at risk of chronic liver disease (CLD). It operates as a secure, intuitive, and easy-to-use system capable of reviewing millions of data lines in seconds to pinpoint patients who fulfill specified criteria. Additionally, its features encompass comprehensive data analysis, machine learning algorithms, real-time risk stratification, and a user-friendly interface.
Liver Diseases Therapeutics Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.
View The Full Liver Diseases Therapeutics Market Report:
Liver Diseases Therapeutics Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
